Document:

Exhibit 10.1

 

ALLONGE TO CONVERTIBLE PROMISSORY NOTES

 

Allonge (this “Allonge”)
to those certain Convertible Promissory Notes (as amended, the “Convertible Promissory Notes”) referenced hereto in
Exhibit 1 and made a part hereof, in each case from Bionik Laboratories Corp. (“Borrower”), to the Holders described
therein (the “Holders”).

 

WHEREAS, Section 7.6
of the Convertible Promissory Notes provides, in part, that the Note may be amended with the written consent of the Company and
the holders of a majority in original aggregate principal amount of the Note and the Related Notes (as defined in the Convertible
Promissory Notes), and that any such amendment shall be binding on all holders of the Convertible Promissory Notes, even if they
do not execute such consent, amendment or waiver.

 

Borrower and the undersigned
Holders, which represent a majority in original aggregate principal amount of the Note and the Related Notes, agree that each of
the Convertible Promissory Notes shall be revised as follows:

 

1.       The
definition of “Qualified Financing” in Section 1.1 of each of the Convertible Promissory Notes shall be amended and
replaced to read as follows:

 

““Qualified
Financing” means an equity or equity-linked round of financing of the Company in whatever form or type that raises,
between January 1, 2018 and March 31, 2018, in one or more tranches aggregate gross proceeds of a minimum of $2,000,000.”

 

2.       Section
3.1(a) of each of the Convertible Promissory Notes shall be amended and replaced to read as follows:

 

(a)       Conversion
upon Maturity Date. Upon a Maturity Date event specified in clause (a) of the definition thereof, without any action on the
part of the Holder, the (i) outstanding principal, (ii) accrued and unpaid interest under the Notes and (iii) the Premium, will
be converted into shares of Common Stock based upon the lesser of (A) the lowest conversion price of New Round Stock in case there
is more than one tranche of New Round Stock or (B) twenty-five cents ($0.25).

 

This Allonge is intended
to be attached to and made a permanent part of the Convertible Promissory Notes.

 

Dated as of the 30th
day of March, 2018.

 

 

 

[Remainder
of Page Intentionally left Blank; Signature Page in Counterparts Follows]

 

    	 

     

    

 

	Maker:	 	BIONIK LABORATORIES CORP.
	 	 	 	 	 
		 	 	 	 
	/s/                                                              	 	By:	/s/ Eric Dusseux	 
	 	 	Name:	 Eric Dusseux	 
	 	 	Title:	CEO	 

 

    	 

     

    

 

Agreed to and consented to pursuant to
Section 7.6 of the Convertible Promissory Notes:

 

	Holder:	 	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/   	 
	 	Name:	 	 
	 	Title:	 	 
	 	 	 	 
	 	 	 	 
	 	 	 
	 	Aggregate Principal Amount
of Convertible Promissory Notes	 

 

    	 

     

    

 

Exhibit 1

 

	RGD Investissements, as Holder	 	 
	Convertible Note	$16,666.66	12/23/2016
	Convertible Note	$16,666.66	1/24/2017
	Convertible Note	$16,666.66	2/17/2017
	Convertible Note	$500,000.00	3/28/2017
	Convertible Note	$150,000.00	8/14/2017
	Convertible Note	$150,000.00	8/29/2017
	Convertible Note	$29,350.00	9/14/2017
	Convertible Note	$100,000.00	10/2/2017
	Convertible Note	$300,000.00	10/17/2017
	Convertible Note	$500,000.00	10/30/2017
	Convertible Note	$600,000.00	11/27/2017
	 	 	 
	Star SCI, as Holder	 	 
	Convertible Note	$50,000.00	8/14/2017
	Convertible Note	$50,000.00	8/28/2017
	Convertible Note	$100,000.00	9/14/2017
	Convertible Note	$300,000.00	9/28/2017
	 	 	 
	Lombard, as Holder	 	 
	Convertible Note	$33,333.33	12/22/2016
	Convertible Note	$33,333.33	1/26/2017
	Convertible Note	$33,333.33	2/15/2017
	 	 	 
	Lombard, as Holder	 	 
	Convertible Note	$166,666.67	12/28/2017
	Convertible Note	$166,666.67	1/26/2017
	Convertible Note	$166,666.67	2/15/2017
	 	 	 
	Solomar SA, as Holder	 	 
	Convertible Note	$166,666.67	12/22/2016
	Convertible Note	$166,666.67	1/25/2017
	Convertible Note	$166,666.67	2/15/2017
	 	 	 
	Guy Grinberg, as Holder	 	 
	Convertible Note	$50,000.00	1/11/2017
	 	 	 
	ECI, as Holder	 	 
	Convertible Note	$100,000.00	12/22/2016
	Convertible Note	$99,975.00	1/26/2017
	Convertible Note	$100,000.00	2/16/2017
	Convertible Note	$240,000	9/14/017

 

    	 

     

    

 

	RREI, as Holder	 	 
	Convertible Note	$150,000.00	10/17/2017
	 	 	 
	Alain Krzentowski, as Holder	 	 
	Convertible Note	$50,000.00	10/18/2017
	 	 	 
	Rouillon, as Holder	 	 
	Convertible Note	$30,000.00	9/14/2017
	 	 	 
	Jean-Pierre Barjon, as Holder	 	 
	Convertible Note	$200,000.00	12/6/2017Exhibit 10.2

 

ALLONGE TO COMMON STOCK PURCHASE WARRANT

 

Allonge (this “Allonge”)
to that certain Common Stock Purchase Warrant, as amended (as so amended, the “Warrant”), attached hereto as Exhibit
1 from Bionik Laboratories Corp. (the “Company”), and issued to the undersigned (the “Holder”). Capitalized
terms used herein and not otherwise defined shall have the meanings ascribed to those terms in the Warrant.

 

The Company and Holder
agree that the Warrant shall be revised as follows:

 

		1.	Notwithstanding anything to the contrary in the Warrant (including any provision requiring the
reservation of sufficient shares to provide for the issuance of Common Stock thereunder), any of the offering documents to which
the Warrant was a part (including any subscription agreement and promissory note) or any other document referred to in or contemplated
by the Warrant, if and to the extent the Company does not have sufficient authorized but unissued shares of Common Stock to issue
to the Holder upon an exercise of the Warrant, the Warrant shall not be exercisable to the extent of such deficiency and the Company
shall use its commercially reasonable efforts to seek and obtain requisite consent to (a) effect a reverse stock split of the Company’s
Common Stock that allows for the issuance of the shares of Common Stock pursuant to the Warrant without violating the authorized
share number of the Company and/or (b) increase the Company’s authorized shares of Common Stock.

 

Except as
expressly reflected herein, the Warrant will remain in full force and effect. This Allonge is intended to be attached to and made
a permanent part of the Warrant.

 

Dated as of the 30th
day of March, 2018.

 

	The Company:	BIONIK LABORATORIES CORP.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  Eric Dusseux	 
	 	Name:	 Eric Dusseux	 
	 	Title:	CEO	 
	 	 	 	 
	 	 	 	 
	Holder:	 	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ 	 
	 	Name:	 	 
	 	Title:Exhibit 10.3

 

EXCHANGE AGREEMENT

 

THIS EXCHANGE AGREEMENT
(this “Agreement”) is dated as of the 30th day of March, 2018 (the “Effective Date”),
by and between Bionik Laboratories Corp., a Delaware corporation (the “Company”), and RGD Investissements S.A.S
(the “Holder”).

 

WHEREAS, the Holder
beneficially owns and holds that certain Promissory Note, dated as of March 14, 2018, issued by the Company, in the principal amount
of $400,000 (the “$400K Note”); and

 

WHEREAS, the Holder
desires to exchange the $400K Note for one of the Company’s Convertible Promissory Notes (the “Exchange Security”)
pursuant to the Company’s convertible note offering of up to $14,000,000 (the “Offering”), and the Company
desires to issue the Exchange Security in exchange for the $400K Note, all on the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, in
consideration of the terms and conditions contained herein, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Company and the Holders hereby agree as follows:

 

Section 1. Exchange.
On the Effective Date, subject to and upon the terms and conditions set forth in this Agreement, the Holder shall surrender to
the Company the $400K Note and all of the rights, covenants, agreements and obligations set forth therein or contemplated thereby,
including but not limited to any interest accrued and unpaid on the principal amount of the $400K Note (collectively, the “Rights”),
and, in exchange therefore, the Company shall issue to the Holder the Exchange Security, with an issue date as of March 14, 2018.
The Exchange Security shall be substantially the same as the convertible promissory notes issued by the Company pursuant to the
Offering. Upon the Effective Date, the Holder will not have any interest or title in or to the $400K Note or the Rights.

 

Section 2. Ownership
and Interest. The Holder is the record and beneficial owner of the $400K Note and the Rights, free and clear of all liens,
charges, pledges, security interests, claims, mortgages, options, encumbrances, rights of first refusal, conditions, covenants,
and other restrictions (other than any restrictions under the Securities Act of 1933, as amended, or state securities laws).

 

Section 3. Applicable
Law. This Agreement shall be construed in accordance with and governed by the laws of the State of Delaware without regard
to its conflict of law rules.

 

Section 4. Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile
signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if
the signature were an original, not a facsimile signature.

 

Section 5. Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.

 

    	 

     

    

 

Section 6. Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

 

Section 7. Entire
Agreement; Amendments. This Agreement and the Exchange Security supersede all other prior oral or written agreements between
the Holder, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and
this Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters
covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Holder makes any
representation, warranty, covenant or undertaking with respect to such matters; provided, however, that all representations and
warranties contained in that certain Subscription Agreement, dated as of March 8, 2018, shall be incorporated herein. No provision
of this Agreement may be amended other than by an instrument in writing signed by the Company and the Holder. No provision hereof
may be waived other than by an instrument in writing signed by the party against whom enforcement is sought.

 

Section 8. Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns. The Holder may not assign any of its rights hereunder without the prior written consent of the Company.

 

Section 9. No Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

Section 10. Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

 

[Signature Pages
Follow]

 

    	 

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Exchange Agreement as of the date first written above.

 

	 	BIONIK LABORATORIES CORP.
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Eric Dusseux	 
	 	Name:	Eric Dusseux	 
	 	Title:	CEO	 
	 	 	 	 
	 	 	 	 
	 	RGD INVESTISSEMENTS S.A.S	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Remi Gaston-Dreyfus	 
	 	Name:	Remi Gaston-Dreyfus	 
	 	Title:	CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]